Findings

What do systematic reviews say?

75 questions · 77 findings · 6 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 23 · 29.9%GRADE not reported 0 · 0%Very low 29 · 37.7%Low 14 · 18.2%Moderate 11 · 14.3%High 0 · 0%

Hydroxyurea vs observation

Measures of HbF · adults and children with sickle cell disease and an increased risk of stroke

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Very low

Hydroxyurea vs observation

Measures of ANC · adults and children with sickle cell disease and an increased risk of stroke

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Very low

Hydroxyurea vs placebo

Life‐threatening illness · people with sickle cell disease

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 759 participants
Moderate

Hydroxyurea vs observation

Quality of life · adults and children with sickle cell disease and an increased risk of stroke

The review found no eligible studies for this question.

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hydroxyurea vs observation

Adverse events or toxicity: differences in rates of specific adverse events · adults and children with sickle cell disease and an increased risk of stroke

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Very low

Hydroxyurea vs placebo

Measures of HbF · people with sickle cell disease

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 784 participants
Low

Hydroxyurea vs placebo

Measures of ANC · people with sickle cell disease

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 724 participants
Moderate

Hydroxyurea vs placebo

Health status and quality of life · people with sickle cell disease

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 277 participants
Low

Hydroxyurea vs placebo

Adverse events or toxicity: differences in rates of specific adverse events · people with sickle cell disease

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 784 participants
Low

Summary of findings ‐ Hydroxyurea and phlebotomy vs transfusion and chelation

All‐cause mortality · adults and children with sickle cell disease and an increased risk of stroke

Summary of findings ‐ Hydroxyurea and phlebotomy showed no clear difference in death during the study (all deaths) compared with transfusion and chelation (low certainty).

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
RR 0.99 [0.06, 15.42]
2 studies · 254 participants
Low

Summary of findings ‐ Hydroxyurea and phlebotomy vs transfusion and chelation

Measures of HbF · adults and children with sickle cell disease and an increased risk of stroke

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 254 participants
Moderate

Summary of findings ‐ Hydroxyurea and phlebotomy vs transfusion and chelation

Measures of ANC · adults and children with sickle cell disease and an increased risk of stroke

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 254 participants
Moderate

Summary of findings ‐ Hydroxyurea and phlebotomy vs transfusion and chelation

Quality of life · adults and children with sickle cell disease and an increased risk of stroke

The review found no eligible studies for this question.

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ Hydroxyurea and phlebotomy vs transfusion and chelation

Adverse events or toxicity: differences in rates of specific adverse events · adults and children with sickle cell disease and an increased risk of stroke

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 254 participants
Low

Summary of findings ‐ Hydroxyurea and phlebotomy vs transfusion and chelation

Pain alteration: proportion experiencing serious VOC or sickle‐related pain events · adults and children with sickle cell disease and an increased risk of stroke

Summary of findings ‐ Hydroxyurea and phlebotomy may leads to higher pain alteration: proportion experiencing serious VOC or… compared with transfusion and chelation (low certainty).

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
RR 3.37 [1.59, 7.11]
2 studies · 254 participants
Low

Summary of findings ‐ Hydroxyurea and phlebotomy vs transfusion and chelation

Life‐threatening illness · adults and children with sickle cell disease and an increased risk of stroke

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 254 participants
Moderate

Long‐term red cell transfusion vs hydroxyurea and phlebotomy

Stroke · individuals with sickle cell disease who are at risk of a primary stroke who have had long‐term red cell transfusions to prevent a stroke

1 finding from 1 review

Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 121 participants
Very low

Long‐term red cell transfusion vs hydroxyurea and phlebotomy

All‐cause mortality · individuals with sickle cell disease who are at risk of a primary stroke who have had long‐term red cell transfusions to prevent a stroke

1 finding from 1 review

Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 121 participants
Very low

Long‐term red cell transfusion vs hydroxyurea and phlebotomy

Adverse events associated with transfusion · individuals with sickle cell disease who are at risk of a primary stroke who have had long‐term red cell transfusions to prevent a stroke

1 finding from 1 review

Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 121 participants
Low

Long‐term red cell transfusion vs hydroxyurea and phlebotomy

Incidence of TIA · individuals with sickle cell disease who are at risk of a primary stroke who have had long‐term red cell transfusions to prevent a stroke

It is very uncertain whether long‐term red cell transfusion changes incidence of TIA compared with hydroxyurea and phlebotomy (very low certainty).

1 finding from 1 review

Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease 2020 · Cochrane Headline outcomes only
RR 1.02 [0.21, 4.84]
1 study · 121 participants
Very low